BUPRENORPHINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for buprenorphine hydrochloride and what is the scope of patent protection?

Buprenorphine hydrochloride is the generic ingredient in ten branded drugs marketed by Bdsi, Reacx Pharms, Indivior, Am Regent, Hikma, Hospira, Ph Health, Somerset Theraps Llc, Actavis Elizabeth, Ascent Pharms Inc, Barr, Ethypharm, Pharmobedient, Rhodes Pharms, Rubicon Research, Specgx Llc, Sun Pharm, Alvogen, Difgen Pharms, Dr Reddys Labs Sa, Mylan Technologies, Teva Pharms Usa, Alkem Labs Ltd, Amneal Pharms, Lannett Co Inc, Wes Pharma Inc, and Edenbridge Pharms, and is included in forty-four NDAs. There are eighteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Buprenorphine hydrochloride has seventy-six patent family members in twenty-seven countries.

There are sixteen drug master file entries for buprenorphine hydrochloride. Twenty-one suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for BUPRENORPHINE HYDROCHLORIDE

International Patents:	76
US Patents:	18
Tradenames:	10
Applicants:	27
NDAs:	44
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	537
Patent Applications:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BUPRENORPHINE HYDROCHLORIDE
What excipients (inactive ingredients) are in BUPRENORPHINE HYDROCHLORIDE?	BUPRENORPHINE HYDROCHLORIDE excipients list
DailyMed Link:	BUPRENORPHINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for BUPRENORPHINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE3
Braeburn Inc	PHASE4
Atea Pharmaceuticals, Inc.	PHASE1

See all BUPRENORPHINE HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for BUPRENORPHINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL
		EQ 2.9MG BASE;EQ 0.71MG BASE	TABLET;SUBLINGUAL
		EQ 11.4MG BASE;EQ 2.9MG BASE	TABLET;SUBLINGUAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for BUPRENORPHINE HYDROCHLORIDE

Drug Class	Partial Opioid Agonist
Mechanism of Action	Partial Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for BUPRENORPHINE HYDROCHLORIDE

N02AE	Oripavine derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

N07BC	Drugs used in opioid dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for BUPRENORPHINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELBUCA	Buccal Film	buprenorphine hydrochloride	75 mcg and 150 mcg	207932	1	2016-10-24
BELBUCA	Buccal Film	buprenorphine hydrochloride	300 mcg, 450 mcg, 600 mcg and 750 mcg	207932	1	2016-10-04
BELBUCA	Buccal Film	buprenorphine hydrochloride	900 mcg	207932	1	2016-09-12

US Patents and Regulatory Information for BUPRENORPHINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	BUPRENORPHINE HYDROCHLORIDE	buprenorphine hydrochloride	TABLET;SUBLINGUAL	218473-001	Dec 10, 2025	AB	RX	No	No
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-002	Jul 3, 2013		RX	Yes	No	11,433,066
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-007	Oct 23, 2015		RX	Yes	Yes	9,655,843		Y
Amneal Pharms	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	203136-002	Feb 22, 2013	AB	RX	No	No
Bdsi	BUNAVAIL	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL	205637-002	Jun 6, 2014		DISCN	Yes	No	8,703,177		Y
Actavis Elizabeth	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	091422-002	Feb 22, 2013	AB	RX	No	No
Dr Reddys Labs Sa	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	206953-001	Jul 17, 2020		DISCN	No	No

Expired US Patents for BUPRENORPHINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015	6,159,498
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015	6,159,498
Reacx Pharms	PROBUPHINE	buprenorphine hydrochloride	IMPLANT;IMPLANTATION	204442-001	May 26, 2016	7,736,665
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-003	Oct 23, 2015	6,159,498
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-004	Oct 23, 2015	6,159,498
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015	7,579,019
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-007	Oct 23, 2015	7,579,019

International Patents for BUPRENORPHINE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Serbia	54764
Spain	2577390
Russian Federation	2013141051	СПОСОБ ТРАНСМУКОЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВА, СРЕДСТВО ТРАНСМУКОЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВА (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ БОЛИ
New Zealand	594545	TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE CONTAINING FENTANYL OR BUPRENORPHINE
Slovenia	2054031
Russian Federation	2019118034
Norway	20200273	Transmukosal leveringsanordning med forøket opptak

Market Dynamics and Financial Trajectory for Buprenorphine Hydrochloride

Last updated: March 4, 2026

What are the current market forces influencing Buprenorphine Hydrochloride?

Buprenorphine Hydrochloride is a partial opioid agonist indicated primarily for opioid dependence treatment, pain management, and as part of opioid addiction therapy. The market is shaped by regulatory policies, healthcare needs, competition, and evolving formulations.

Key Market Drivers

• Rising Opioid Addiction Rates: The US has experienced a surge in opioid use disorder, increasing demand for buprenorphine-based therapies. According to the CDC, opioid overdose deaths increased by 15% annually between 2015-2020 [1].
• Government Policy and Regulations: The Drug Addiction Treatment Act (DATA 2000), expanded the scope of providers authorized to prescribe buprenorphine. Recent policy shifts aim to reduce barriers to access.
• Reimbursement and Insurance Coverage: Increasing insurance coverage, including Medicaid expansion, enhances patient access to buprenorphine treatments.
• Development of New Formulations: The advancement of abuse-deterrent formulations and long-acting injectables broadens therapeutic options, appealing to a wider patient demographic.

Challenges and Constraints

• Regulatory Barriers: Stringent prescription guidelines and the Drug Enforcement Administration (DEA) controls limit prescribing.
• Societal Stigma: Stigma associated with opioid addiction impacts treatment uptake.
• Market Competition: Besides buprenorphine, other medications like methadone and naltrexone are competing options.
• Pricing Pressures: Payers' cost containment efforts influence drug pricing strategies.

Market Size and Growth

The global buprenorphine market was valued at approximately USD 4.2 billion in 2022. Projections estimate a compound annual growth rate (CAGR) of 6.8% from 2023 to 2030, reaching USD 8 billion by 2030 [2].

Year	Market Size (USD billion)
2022	4.2
2025	~5.5
2030	8.0

North America holds roughly 70% of the market share due to high opioid use disorder prevalence and extensive healthcare infrastructure. Europe follows with 18%, driven by increasing addiction treatment initiatives.

How do pharmaceutical companies generate revenue through Buprenorphine Hydrochloride?

Revenue streams mainly derive from drug sales—both generic and branded formulations. Key companies include Indivior, MundiPharma, and Teva Pharmaceuticals.

Commercial Strategies

• Brand vs. Generic: Branded products like Suboxone (combination of buprenorphine and naloxone) command higher prices, while generics offer cost advantages.
• Formulation Innovation: Once-weekly depot injections and implant options aim to improve adherence and extend market reach.
• Global Expansion: Entering emerging markets facing rising opioid addiction issues tailored to local regulatory frameworks.

Pricing Benchmarks (2022)

• Suboxone film: Retail price around USD 490 per month.
• Generic buprenorphine tablets: USD 120–USD 150 per month.
• Long-acting injections (AMF-202): Estimated at USD 1,200 per dose.

Pricing remains sensitive to reimbursement policies and generic competition.

What are the key financial trends observable in the buprenorphine market?

• Revenue Growth: Major players report double-digit revenue growth, driven by increased demand and expanded indications.
• Profitability: Branded formulations with patent exclusivity generate higher margins; generics compress profit margins.
• Research and Development (R&D): Increased R&D investment in extended-release formulations predates new product launches, which can increase capital expenditure but promise higher future revenues.

What future market opportunities and risks exist?

Opportunities:

• Regulatory Approvals for Novel Formulations: Long-acting injectables and implants for sustained release.
• Emerging Markets: Countries with rising opioid addiction rates provide expansion avenues.
• Diversification: Use in pain management and multimodal therapy.

Risks:

• Regulatory Changes: Stricter prescribing regulations or scheduling could limit access.
• Patent Expirations: Loss of exclusivity for leading brand products presses profit margins.
• Public Perception: Increased scrutiny over opioid medications may impact prescriber behavior.

Key Financial Projections (2023–2030)

Year	Estimated Global Revenue (USD billion)	CAGR	Notes
2023	4.5	6.8%	Post-pandemic market stabilization
2025	5.5	6.8%	Increased adoption and formulation innovation
2030	8.0	6.8%	Market maturity with expanded access

Key Takeaways

• The buprenorphine hydrochloride market exhibits steady growth driven by the opioid crisis, regulatory support, and formulation innovation.
• North America dominates the market, with growing opportunities in Europe and emerging economies.
• Revenue generation relies heavily on branded formulations, though generics are increasing market penetration.
• Innovations in extended-release and implant forms create future revenue streams.
• Regulatory, patent, and societal challenges pose ongoing risks.

FAQs

1. Which companies lead the buprenorphine hydrochloride market?

Indivior and Teva Pharmaceuticals dominate, especially through branded products like Suboxone. MundiPharma and others also hold significant market share in generics.

2. What are the primary formulations of buprenorphine hydrochloride?

Available forms include sublingual films, tablets, injectable long-acting versions, and implants.

3. How do regulatory changes impact the market?

Regulatory authorities can restrict prescribing privileges or tighten scheduling, affecting sales volume and distribution channels.

4. What is the pipeline of future formulations?

Long-acting injectables with weekly or monthly dosing schedules are in late-stage development, aiming to improve adherence and reduce diversion risk.

5. What factors could slow market growth?

Policy restrictions, social stigma, or patent expirations could reduce revenue growth rates or market size.

References

[1] Centers for Disease Control and Prevention. (2021). Opioid overdose deaths. https://www.cdc.gov/drugoverdose/data/statedeaths.html

[2] Grand View Research. (2022). Buprenorphine Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com/industry-analysis/buprenorphine-market